KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Net Cash Flow: 2009-2024

Historic Net Cash Flow for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $134.0 million.

  • Acadia Pharmaceuticals' Net Cash Flow rose 123.01% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.6 million, marking a year-over-year increase of 72.64%. This contributed to the annual value of $134.0 million for FY2024, which is 81.54% up from last year.
  • According to the latest figures from FY2024, Acadia Pharmaceuticals' Net Cash Flow is $134.0 million, which was up 81.54% from $73.8 million recorded in FY2023.
  • Over the past 5 years, Acadia Pharmaceuticals' Net Cash Flow peaked at $137.3 million during FY2020, and registered a low of -$178.6 million during FY2021.
  • Moreover, its 3-year median value for Net Cash Flow was $73.8 million (2023), whereas its average is $58.4 million.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Net Cash Flow crashed by 230.04% in 2021, and later spiked by 326.50% in 2023.
  • Yearly analysis of 5 years shows Acadia Pharmaceuticals' Net Cash Flow stood at $137.3 million in 2020, then slumped by 230.04% to -$178.6 million in 2021, then surged by 81.75% to -$32.6 million in 2022, then spiked by 326.50% to $73.8 million in 2023, then soared by 81.54% to $134.0 million in 2024.